In liver cancer, AZGP1 has been found to inhibit the TGF-β1-ERK2 pathway, PTEN/Akt pathway, the CD44 signaling pathway [18, 19], and epithelial-to-mesenchymal transition (EMT). Here, AZGP1 is linked to liver cancer.